British Columbia Adds Renflexis, a Remicade Biosimilar for Crohn’s, UC, to Public Drug Plan

British Columbia Adds Renflexis, a Remicade Biosimilar for Crohn’s, UC, to Public Drug Plan
Renflexis (infliximab-abda), Merck’s biosimilar of Remicade (infliximab), has been added to the public drug plan of the Canadian province of British Columbia. As of Aug. 21, adults and children with Crohn's disease and ulcerative colitis, as well as other approved indications, can now be reimbursed for the costs associated with Renflexis treatment. "We are pleased to see the government of British Columbia add Renflexis to its formulary, which offers effective and more affordable treatment options for patients impacted by these diseases," Manon Lafontaine, vice president of patient access at Merck Canada, said in a press release. "We're committed to continuing to work with provinces and territories throughout Canada to ensure broader access for all patients to the care they need." Renflexis, which is manufactured by Samsung Bioepis, is a similar, cheaper version of brand-name Remicade. It is marketed and distributed in the U.S. and Canada by Merck, known as MSD outside these countries. It cons
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *